Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2020 | Pages:
105 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The U.S. platelet rich plasma market size is estimated to generate USD 364.6 million by 2027, expanding at a CAGR of 10.3%, according to a new report by Grand View Research, Inc. Platelet-rich plasma (PRP) has gained significant popularity in the field of orthopedics, neurosurgery, ophthalmology, and cosmetic surgery as it integrates modern technology with the body's capability to accelerate healing. A rise in the incidence of musculoskeletal disorders, orthopedic disorders, and sports injuries has encouraged clinicians to embrace minimally invasive platelet rich plasma therapy with less risk of therapy-associated adverse effects, which propels the market growth. As per the International Osteoporosis Foundation, around 52.0 million people suffered from osteoporosis or low bone mass in 2010 and are expected to reach 61.0 million by 2020 in the U.S. Besides, platelet rich plasma injections have been highlighted in numerous medical journals as a promising technique to heal damaged tissues. The studies have reported improved function and lesser pain after receiving these therapies than traditional standard care, thus driving its adoption rate. Platelet rich plasma-based therapies continue to evolve as a popular treatment in the dermatology field. It is increasingly being preferred for skin rejuvenation, hair restoration, dermal augmentation, acne scars, and striae distensae. Moreover, the combination of platelet rich plasma with laser therapies, dermal fillers, micro-needling, and autologous fat grafting generates synergistic effects that lead to optimized aesthetic outcomes. The confluence of these factors boosts the penetration of these therapies in dermatology applications. The emergence of platelet rich plasma products for point-of-care settings is another factor fostering market progression. Several POC systems are available in the market place that is specifically engineered and validated to deliver fast POC treatments within a few minutes. HEALEON HD PRP from HEALEON MEDICAL, INC., is one such FDA-approved Class II medical device that is designed for autologous platelet rich plasma preparation at the patient’s POC settings. U.S. Platelet Rich Plasma Market Report Highlights • The leukocyte-rich platelet rich plasma segment is expected to witness a significant increase in the commercial pool and number of experimental studies expanding its applications across orthopedic, general surgery, and sports medicine • Numerous advancements in leukocyte PRP market space by manufacturers, mainly in protocol automation to maximize the standardization of plasma preparations are driving the segment • The cosmetic surgery and dermatology application segment is expected to foresee the highest growth rate during the overcast period • This is due to a rapid increase in preference among the consumers as injections based on this therapy help to achieve fuller facial features without opting for commercial fillers • Platelet rich plasma systems are estimated to witness the fastest growth rate throughout the forecast period in the sports medicine application • The advent of novel separation systems by key manufacturers that are specific to platelet rich plasma applications as well as functions vertically and are applicable across autologous cellular therapies boost the growth of these systems • Numerous medical visits, high burden of orthopedic disorders particularly in geriatric population, and widespread application of this therapy for musculoskeletal injuries result in the dominant share of hospitals in 2019 • More than 300,000 old aged people, over 65 years, are hospitalized for hip fractures every year in the U.S. • This high hospitalization rate surges the incorporation of platelet rich plasma as an adjunctive use in hip surgeries in hospital settings • Key manufacturers are implementing business strategies such as broadening of product portfolio, widening of distribution network, and collaborations and mergers to reinforce their significant share in the market.
Table of Contents
Chapter 1 The U.S. Platelet Rich Plasma (PRP) Market: Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased database
1.4.2 GVR’sinternal database
1.4.3 Secondary sources
1.4.4 Primary research
1.4.5 Details of primary research
1.5 Information or Data Analysis
1.5.1 The U.S. platelet rich plasma (PRP) market: Segment revenue and growth analysis
1.5.2 Data analysis models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity flow analysis
1.7.1.1 Approach 1: Commodity flow approach
1.7.1.2 Approach 2: Country-wise market estimation using bottom up approach
1.8 The U.S. Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
Chapter 2 The U.S. Platelet Rich Plasma (PRP) Market: Executive Summary
2.1 Market Outlook
2.2 Competition Milieu
2.3 Segment Outlook
2.4 Market Summary, 2019 (USD Million)
Chapter 3 The U.S. Platelet Rich Plasma (PRP) Market: Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Parent Market Lineage
3.3 Market Dynamics
3.3.1 Market drivers analysis
3.3.1.1 Rise in the incidence of orthopedic disorders and sports injuries
3.3.1.2 Increasing number of cosmetic surgery procedures
3.3.1.3 Extending medical applications of platelet rich plasma
3.3.2 Market restraint analysis
3.3.2.1 High costs associated with PRP products
3.4 Penetration & Growth Prospect Mapping, by Application, 2019
Chapter 4 The U.S. Platelet Rich Plasma (PRP) Market: Business Environment Analysis
4.1 SWOT Analysis; by Factor (Political & Legal, Economic and Technological)
4.2 Porter’s Five Forces Analysis
Chapter 5 The U.S. Platelet Rich Plasma (PRP) Market: Type Business Analysis
5.1 The U.S. Platelet Rich Plasma (PRP) Market: Type Movement Analysis
5.2 Pure PRP
5.2.1 The U.S. pure PRP market estimates and forecast, 2016 - 2027 (USD Million)
5.3 Leukocyte Rich PRP
5.3.1 The U.S. leukocyte rich PRP market estimates and forecast, 2016 - 2027 (USD Million)
5.4 Others
5.4.1 The U.S. PRP market estimates and forecast for others, 2016 - 2027 (USD Million)
Chapter 6 The U.S. Platelet Rich Plasma (PRP) Market: Application Business Analysis
6.1 Orthopedics
6.1.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for orthopedics, 2016 - 2027 (USD Million)
6.2 Sports Medicine
6.2.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for sports medicine, 2016 - 2027 (USD Million)
6.2.2 PRP injections
6.2.2.1 The U.S. platelet rich plasma (PRP) injections market estimates and forecast for sports medicine, 2016 - 2027 (USD Million)
6.2.3 PRP kits
6.2.3.1 The U.S. platelet rich plasma (PRP) kits market estimates and forecast for sports medicine, 2016 - 2027 (USD Million)
6.2.4 PRP systems
6.2.4.1 The U.S. platelet rich plasma (PRP) systems market estimates and forecast for sports medicine, 2016 - 2027 (USD Million)
6.3 Cosmetic Surgery and Dermatology
6.3.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for cosmetic surgery and dermatology, 2016 - 2027 (USD Million)
6.4 Ophthalmic Surgery
6.4.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for ophthalmic surgery, 2016 - 2027 (USD Million)
6.5 Neurosurgery
6.5.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for neurosurgery, 2016 - 2027 (USD MILLION)
6.6 General Surgery
6.6.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for general surgery, 2016 - 2027 (USD Million)
6.7 Others
6.7.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for others, 2016 - 2027 (USD Million)
Chapter 7 U.S. Platelet Rich Plasma (PRP) Market: End-Use Business Analysis
7.1 The U.S. Platelet Rich Plasma (PRP) Market: End-use Movement Analysis
7.2 Hospitals
7.2.1 The U.S. platelet rich plasma (PRP) market for hospitals, 2016 - 2027 (USD Million)
7.3 Clinics
7.3.1 The U.S. platelet rich plasma (PRP) market for clinics, 2016 - 2027 (USD Million)
7.4 Others
7.4.1 The U.S. platelet rich plasma (PRP) market for others, 2016 - 2027 (USD Million)
Chapter 8 The U.S. Platelet Rich Plasma (PRP) Market: Company Profile
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 Johnson & Johnson
8.3.1.1 Company overview
8.3.1.2 DePuy Synthes
8.3.1.2.1 Company overview
8.3.1.3 Financial performance
8.3.1.4 Product benchmarking
8.3.1.5 Strategic initiatives
8.3.2 Arthrex, Inc.
8.3.2.1 Company overview
8.3.2.3 Financial performance
8.3.2.4 Product benchmarking
8.3.2.5 Strategic initiatives
8.3.3 EmCyte Corporation
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 DR. PRP America, LLC
8.3.4.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.5 Juventix
8.3.5.1 Company overview
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 Terumo Corporation
8.3.6.1 Company overview
8.3.6.2 Terumo BCT, Inc.
8.3.6.2.1 Company overview
8.3.6.3 Financial performance
8.3.6.4 Product benchmarking
8.3.6.5 Strategic initiatives
8.3.7 Zimmer Biomet
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 Stryker
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
List of Tables Table 1 List of secondary sources Table 2 Growth factors involved in stages of wound healing Table 3 Growth factors involved in wound healing with their origin Table 4 Use of PRP in wound management Table 5 Products and service providers: Knee OA injectable biologics Table 6 Clinical trials performed until 2017 to supporting the data efficacy of biologics in sports medicine Table 7 Manufacturers operating in the pure PRP market space List of Figures Fig. 1 Market research process Fig. 2 Data triangulation techniques Fig. 3 Primary research pattern Fig. 4 The U.S. PRP segment revenue modeling Fig. 5 The U.S. sports medicine market segment revenue modeling Fig. 6 Market research approaches Fig. 7 Value chain-based sizing & forecasting Fig. 8 QFD modeling for market share assessment Fig. 9 Market formulation & validation Fig. 10 The U.S. platelet rich plasma (PRP) market snapshot, 2019 (USD Million) Fig. 11 The U.S. platelet rich plasma (PRP) market segmentation Fig. 12 Market driver relevance analysis (Current & future impact) Fig. 13 Prevalence rate of arthritis in the U.S. adults, diagnosed and projected cases Fig. 14 Incidence of arthritis in the U.S., by age Fig. 15 Benefits of PRP treatment in cosmetic facial procedures Fig. 16 Common cosmetic surgical procedures in 2019 Fig. 17 Cosmetic plastic demographic data in 2019 Fig. 18 Common minimal invasive procedures in 2019, U.S. Fig. 19 Market restraint relevance analysis (Current & future impact) Fig. 20 Penetration and growth prospect mapping, by application, 2019 Fig. 21 The U.S. platelet rich plasma (PRP) market SWOT analysis Fig. 22 The U.S. platelet rich plasma (PRP) market Porter’s five forces analysis Fig. 23 The U.S. platelet rich plasma (PRP) market: Type outlook and key takeaways Fig. 24 The U.S. platelet rich plasma (PRP) market: Type movement analysis Fig. 25 The U.S. pure PRP market estimates and forecast, 2016 - 2027 (USD Million) Fig. 26 The U.S. leukocyte rich PRP market estimates and forecast, 2016 - 2027 (USD Million) Fig. 27 The U.S. PRP market estimates and forecast for others, 2016 - 2027 (USD Million) Fig. 28 The U.S. platelet rich plasma (PRP) market: Application outlook and key takeaways Fig. 29 The U.S. platelet rich plasma (PRP) market: Application movement analysis Fig. 30 The U.S. platelet rich plasma (PRP) market estimates and forecast for orthopedics, 2016 - 2027 Fig. 31 The U.S. platelet rich plasma (PRP) market estimates and forecast for sports medicine, 2016 - 2027 Fig. 32 The U.S. platelet rich plasma (PRP) injections market estimates and forecast for sports medicine, 2016 - 2027 Fig. 33 The U.S. platelet rich plasma (PRP) kits market estimates and forecast for sports medicine, 2016 - 2027 Fig. 34 The U.S. platelet rich plasma (PRP) systems market estimates and forecast for sports medicine, 2016 - 2027 Fig. 35 The U.S. platelet rich plasma (PRP) market estimates and forecast for cosmetic surgery and dermatology, 2016 - 2027 Fig. 36 The U.S. platelet rich plasma (PRP) market estimates and forecast for ophthalmic surgery, 2016 - 2027 Fig. 37 The U.S. platelet rich plasma (PRP) market estimates and forecast for neurosurgery, 2016 - 2027 Fig. 38 The U.S. platelet rich plasma (PRP) market estimates and forecast for general surgery, 2016 - 2027 Fig. 39 The U.S. platelet rich plasma (PRP) market estimates and forecast for others, 2016 - 2027 Fig. 40 The U.S. platelet rich plasma (PRP) market: End-use outlook and key takeaways Fig. 41 The U.S. platelet rich plasma (PRP) market: End-use movement analysis Fig. 42 The U.S. platelet rich plasma (PRP) market for hospitals, 2016 - 2027 (USD Million) Fig. 43 The U.S. platelet rich plasma (PRP) market for clinics, 2016 - 2027 (USD Million) Fig. 44 The U.S. platelet rich plasma (PRP) market for others, 2016 - 2027 (USD Million) Fig. 45 Strategy framework Fig. 46 Market participation categorization
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
